U.S. pharma big copyright scrapped two experimental weight loss supplements last calendar year—a after-day by day tablet, lotiglipron, due to elevated liver enzymes and a 2 times-everyday tablet, danuglipron, resulting from potent Uncomfortable side effects—but CEO Albert Bourla has claimed the company is decided to “Engage in and earn” wit